Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Blocking fatty acid–fueled mROS production within macrophages alleviates acute gouty inflammation
Christopher J. Hall, … , Nicola Dalbeth, Philip S. Crosier
Christopher J. Hall, … , Nicola Dalbeth, Philip S. Crosier
Published March 26, 2018
Citation Information: J Clin Invest. 2018;128(5):1752-1771. https://doi.org/10.1172/JCI94584.
View: Text | PDF
Research Article Immunology Inflammation

Blocking fatty acid–fueled mROS production within macrophages alleviates acute gouty inflammation

  • Text
  • PDF
Abstract

Gout is the most common inflammatory arthritis affecting men. Acute gouty inflammation is triggered by monosodium urate (MSU) crystal deposition in and around joints that activates macrophages into a proinflammatory state, resulting in neutrophil recruitment. A complete understanding of how MSU crystals activate macrophages in vivo has been difficult because of limitations of live imaging this process in traditional animal models. By live imaging the macrophage and neutrophil response to MSU crystals within an intact host (larval zebrafish), we reveal that macrophage activation requires mitochondrial ROS (mROS) generated through fatty acid oxidation. This mitochondrial source of ROS contributes to NF-κB–driven production of IL-1β and TNF-α, which promote neutrophil recruitment. We demonstrate the therapeutic utility of this discovery by showing that this mechanism is conserved in human macrophages and, via pharmacologic blockade, that it contributes to neutrophil recruitment in a mouse model of acute gouty inflammation. To our knowledge, this study is the first to uncover an immunometabolic mechanism of macrophage activation that operates during acute gouty inflammation. Targeting this pathway holds promise in the management of gout and, potentially, other macrophage-driven diseases.

Authors

Christopher J. Hall, Leslie E. Sanderson, Lisa M. Lawrence, Bregina Pool, Maarten van der Kroef, Elina Ashimbayeva, Denver Britto, Jacquie L. Harper, Graham J. Lieschke, Jonathan W. Astin, Kathryn E. Crosier, Nicola Dalbeth, Philip S. Crosier

×

Figure 14

Stearic acid (C18:0) augments MSU crystal–stimulated expression of IL1B and TNFA expression in THP-1 cells through FAO-driven mROS production, and drugs that inhibit Irg1 expression suppress neutrophil recruitment in a murine air pouch model of acute gouty inflammation.

Options: View larger image (or click on image) Download as PowerPoint
Stearic acid (C18:0) augments MSU crystal–stimulated expression of IL1B ...
(A and B) Expression of IL1B (A) and TNFA (B) in THP-1 cells stimulated with MSU crystals, C18:0, MSU crystals plus C18:0, and MSU crystal plus C18:0 in the presence of BAY11-7082, celastrol, triptolide, MitoTEMPO, etomoxir, chrysin, piperlongumine, or camptothecin 6 hours after stimulation, relative to the no–MSU crystals control (qPCR, n = 5 biological replicates). (C) Expression of IRG1 in THP-1 cells stimulated with MSU crystals plus C18:0 alone and in the presence of chrysin, piperlongumine, or camptothecin, measured after 6 hours of stimulation, relative to the no–MSU crystals control (qPCR, n = 5 biological replicates). (D) Representative flow cytometric data showing MitoSOX fluorescence in THP-1 cells stimulated with MSU crystals, MSU crystals plus C18:0, and MSU crystals plus C18:0 in the presence of MitoTEMPO, etomoxir, chrysin, piperlongumine, or camptothecin, measured after 6 hours of stimulation (displayed as counts, percentage of maximum). (E) Quantification of MitoSOX signal (MFI), as detected in D, relative to MSU crystal–treated cells (n = 5 biological replicates). (F–H) Temporal expression of Il1b (F), Tnfa (G), and Irg1 (H) in peritoneal monocytes isolated from mice following intraperitoneal injection of MSU crystals, relative to the no–MSU crystals control (qPCR, n = 5 mice/treatment). (I) Schematic of murine MSU crystal air pouch model of acute gouty inflammation and drug treatment strategy. (J) Effects of chrysin, piperlongumine, and camptothecin on neutrophil and monocyte numbers (measured as a percentage of leukocytes) in the murine MSU crystal air pouch model (n = 5 mice for the no–MSU crystals control; n = 10 mice for all other treatments). Data represent the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with Dunnett’s post hoc test (A–C, E, and J) and Kruskal-Wallis test (F–H).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts